These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29523597)

  • 1. Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.
    Jachetti E; Cancila V; Rigoni A; Bongiovanni L; Cappetti B; Belmonte B; Enriquez C; Casalini P; Ostano P; Frossi B; Sangaletti S; Chiodoni C; Chiorino G; Pucillo CE; Tripodo C; Colombo MP
    Cancer Immunol Res; 2018 May; 6(5):552-565. PubMed ID: 29523597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
    Dzojic H; Loskog A; Tötterman TH; Essand M
    Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
    Fu SY; Chen FH; Wang CC; Yu CF; Chiang CS; Hong JH
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1547-1558. PubMed ID: 33188861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
    Pittoni P; Tripodo C; Piconese S; Mauri G; Parenza M; Rigoni A; Sangaletti S; Colombo MP
    Cancer Res; 2011 Sep; 71(18):5987-97. PubMed ID: 21896641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment.
    Danelli L; Frossi B; Gri G; Mion F; Guarnotta C; Bongiovanni L; Tripodo C; Mariuzzi L; Marzinotto S; Rigoni A; Blank U; Colombo MP; Pucillo CE
    Cancer Immunol Res; 2015 Jan; 3(1):85-95. PubMed ID: 25351848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
    Jayaprakash P; Ai M; Liu A; Budhani P; Bartkowiak T; Sheng J; Ager C; Nicholas C; Jaiswal AR; Sun Y; Shah K; Balasubramanyam S; Li N; Wang G; Ning J; Zal A; Zal T; Curran MA
    J Clin Invest; 2018 Nov; 128(11):5137-5149. PubMed ID: 30188869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
    Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA
    Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
    Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
    J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity.
    Saleem SJ; Martin RK; Morales JK; Sturgill JL; Gibb DR; Graham L; Bear HD; Manjili MH; Ryan JJ; Conrad DH
    J Immunol; 2012 Jul; 189(2):511-5. PubMed ID: 22706087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
    Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
    J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory Role of Surfactant Protein-D in a Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model.
    Ganguly K; Kishore U; Metkari SM; Madan T
    Front Immunol; 2022; 13():930449. PubMed ID: 35874783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.
    Wang X; Ma S; Twardowski P; Lau C; Chan YS; Wong K; Xiao S; Wang J; Wu X; Frankel P; Wilson TG; Synold TW; Presant C; Dorff T; Yu J; Sadava D; Chen S
    Clin Transl Med; 2024 Oct; 14(10):e70048. PubMed ID: 39390760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.